OrthoPediatrics Corp.

NASDAQ:KIDS

Medical - Devices

Healthcare
$31.65 +1.05%

+$0.19 today

Market cap
$826.40M
Beta
1.01
P/E (TTM)
-11.0
EPS (TTM)
-$1.68
52W Low $14.42High $23.70

Volume 0.16M

Average 0.16M

KIDS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

OrthoPediatrics Corp.NASDAQ: KIDS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $2.23M fell 5.1% year over year, ahead of the -13.5% change in trailing-twelve-month research & development. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at +2.5% a year.

Context

  • Research & development amounted to 3.9% of revenue in FY2025, down 1.5 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -5.1% holds above the trailing-twelve-month pace of -13.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.23M-1.2% QoQ
Last fiscal yearDec 2025
$9.1M-17.5% YoY
LTMMar 2026
$8.98M-13.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.1%——
1 year-17.5%——
3-year CAGR+2.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
9.1M USD
Year-over-year change
-17.5%
4-year CAGR
+13.2%

Research & Development vs competitors

How KIDS compares with its peers on the latest reported figures

  • KIDS's LTM Mar 2026 research & development of $8.98M is the 7th highest of the 8 companies compared; the peer median is $19.34M.
  • Its year-over-year change of -13.5% is the 5th highest of 7, against a peer median of -2.4%.
  • Research & development amounts to 3.7% of revenue for KIDS, versus a peer median of 9.3%.
KIDS Competitors Peer median
Research & Development for KIDS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RXSTRxSight, Inc.LTM Mar 2026$37.65M +2.6%+14.1%29.5%
LABStandard BioTools Inc.LTM Mar 2026$22.48M -43.6%-11.4%26.1%
CBLLCeriBell, Inc.LTM Mar 2026$21.06M +43.4%+38.3%22.2%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$19.34M -7.4%+14.3%9.3%
BVSBioventus Inc.LTM Mar 2026$11.57M -19.0%-20.2%2.0%
EOLSEvolus, Inc.LTM Mar 2026$9.6M +3.2%+12.4%3.2%
KIDSOrthoPediatrics Corp.LTM Mar 2026$8.98M -13.5%+2.5%3.7%
TOIThe Oncology Institute, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding KIDS) $19.34M-2.4%+13.2%9.3%

Competitors are the stored peer set for KIDS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue98.05M122.29M148.73M204.73M236.35M
Cost of Revenue24.65M31.63M37.48M56.13M63.69M
Gross Profit73.4M90.66M111.25M148.6M172.66M
Gross Margin74.9%74.1%74.8%72.6%73.1%
Research & Development5.54M8.45M10.9M11.03M9.1M
Selling, General & Admin85.73M104M126.12M167.09M192.56M
Operating Expenses91.43M116.06M138M178.12M201.66M
Depreciation & Amortization10.68M13.1M17.39M19.08M21.25M
EBITDA(7.19M)(8.69M)(8.38M)(20.23M)(11.94M)
EBITDA Margin-7.3%-7.1%-5.6%-9.9%-5.1%
Operating Income(18.02M)(25.4M)(26.75M)(29.52M)(29M)
Operating Margin-18.4%-20.8%-18.0%-14.4%-12.3%
Interest Income00198K00
Interest Expense2.25M2.42M02.62M6M
Other Income / Expenses636K21.71M5.44M(12.41M)(10.19M)
Income Before Tax(17.39M)(3.69M)(21.31M)(41.93M)(39.19M)
Pre-Tax Margin-17.7%-3.0%-14.3%-20.5%-16.6%
Income Tax Expense(1.13M)(4.95M)(338K)(4.11M)460K
Net Income(16.26M)1.26M(20.97M)(37.82M)(39.65M)
Net Margin-16.6%1.0%-14.1%-18.5%-16.8%
EPS (Basic)(0.84)0.06(0.92)(1.64)(1.69)
EPS (Diluted)(0.84)0.06(0.92)(1.64)(1.69)
Weighted Avg Shares19.27M20.7M22.68M23.08M23.46M
Weighted Avg Shares (Diluted)19.27M20.95M22.68M23.08M23.46M

OrthoPediatrics Corp.

NASDAQ:KIDS

Intrinsic Alpha fair value

Locked

Current Price

$31.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.